Guggenheim Increases Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,300.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price increased by Guggenheim from $1,180.00 to $1,300.00 in a research report sent to investors on Friday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Other analysts also recently issued research reports about the company. Royal Bank of Canada restated an outperform rating and issued a $1,229.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday, June 24th. StockNews.com downgraded Regeneron Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Tuesday, April 30th. Truist Financial restated a buy rating and issued a $1,200.00 target price (up previously from $1,135.00) on shares of Regeneron Pharmaceuticals in a research note on Friday. TD Cowen increased their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a buy rating in a research report on Tuesday, July 23rd. Finally, UBS Group increased their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a buy rating in a research report on Wednesday, April 17th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of Moderate Buy and a consensus target price of $1,097.05.

Regeneron Pharmaceuticals Stock Down 1.0 %

Shares of REGN stock opened at $1,071.28 on Friday. Regeneron Pharmaceuticals has a 1-year low of $765.28 and a 1-year high of $1,115.00. The stock’s fifty day moving average price is $1,043.43 and its 200 day moving average price is $983.16. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.96 and a quick ratio of 4.51. The company has a market cap of $118.04 billion, a price-to-earnings ratio of 31.65, a price-to-earnings-growth ratio of 2.34 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same quarter in the previous year, the business earned $8.79 EPS. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, research analysts expect that Regeneron Pharmaceuticals will post 37.38 earnings per share for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the completion of the transaction, the executive vice president now directly owns 37,937 shares in the company, valued at $41,311,496.15. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the completion of the transaction, the executive vice president now directly owns 37,937 shares in the company, valued at $41,311,496.15. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Leonard S. Schleifer sold 25,000 shares of the firm’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now owns 408,200 shares of the company’s stock, valued at $399,729,850. The disclosure for this sale can be found here. Insiders sold a total of 65,074 shares of company stock worth $64,546,123 over the last ninety days. Company insiders own 7.48% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. West Paces Advisors Inc. boosted its holdings in Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares during the period. Stephens Consulting LLC acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at $26,000. Crewe Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at $28,000. MCF Advisors LLC raised its stake in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 12 shares in the last quarter. Finally, Lynx Investment Advisory acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at $33,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.